Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junshan Qiu

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Therapeutic Innovation & Regulatory Science|June 10, 2020
Real-World Evidence Utilization in Clinical Development Reflected by US Product Labeling: Statistical ReviewYodit Seifu, Margaret Gamalo-Siebers, Friederike M-S Barthel, et al.
The Oncologist|February 12, 2020
FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host DiseaseDonna Przepiorka, Lola Luo, Sriram Subramaniam, et al.
Journal of AOAC International|September 14, 2022
Bridging of a Liquid Chromatography-Tandem Mass Spectrometry Method for Oxytetracycline, Chlortetracycline, and Tetracycline in Bovine Kidney with the Official Microbial Growth Inhibition AssayLauren Girard, Hui Li, Charles Feng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2021
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell CarcinomaElaine Chang, Chana Weinstock, Lijun Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast CancerPreeti Narayan, Christy L Osgood, Harpreet Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2023
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian CancerAsma Dilawari, Mirat Shah, Gwynn Ison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2020
FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast CancerJennifer J Gao, Christy L Osgood, Yutao Gong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2025
FDA Approval Summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancerMelanie Royce, Mirat Shah, Lijun Zhang, et al.
Journal of Clinical Microbiology|February 17, 2017
Multilaboratory Survey To Evaluate Salmonella Prevalence in Diarrheic and Nondiarrheic Dogs and Cats in the United States between 2012 and 2014Renate Reimschuessel, Michael Grabenstein, Jake Guag, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2020
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast CancerPreeti Narayan, Tatiana M Prowell, Jennifer J Gao, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Therapeutic Innovation & Regulatory Science|June 10, 2020
Real-World Evidence Utilization in Clinical Development Reflected by US Product Labeling: Statistical ReviewYodit Seifu, Margaret Gamalo-Siebers, Friederike M-S Barthel, et al.
The Oncologist|February 12, 2020
FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host DiseaseDonna Przepiorka, Lola Luo, Sriram Subramaniam, et al.
Journal of AOAC International|September 14, 2022
Bridging of a Liquid Chromatography-Tandem Mass Spectrometry Method for Oxytetracycline, Chlortetracycline, and Tetracycline in Bovine Kidney with the Official Microbial Growth Inhibition AssayLauren Girard, Hui Li, Charles Feng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2021
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell CarcinomaElaine Chang, Chana Weinstock, Lijun Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast CancerPreeti Narayan, Christy L Osgood, Harpreet Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2023
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian CancerAsma Dilawari, Mirat Shah, Gwynn Ison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2020
FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast CancerJennifer J Gao, Christy L Osgood, Yutao Gong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2025
FDA Approval Summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancerMelanie Royce, Mirat Shah, Lijun Zhang, et al.
Journal of Clinical Microbiology|February 17, 2017
Multilaboratory Survey To Evaluate Salmonella Prevalence in Diarrheic and Nondiarrheic Dogs and Cats in the United States between 2012 and 2014Renate Reimschuessel, Michael Grabenstein, Jake Guag, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2020
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast CancerPreeti Narayan, Tatiana M Prowell, Jennifer J Gao, et al.
Pageof 3